Abstract: CD14؉ peripheral blood monocytes can differentiate into fibroblast-like cells called fibrocytes, which are associated with and are at least partially responsible for wound healing and fibrosis in multiple organ systems. Signals regulating fibrocyte differentiation are poorly understood. In this study, we find that when added to human PBMCs cultured in serum-free medium, the profibrotic cytokines IL-4 and IL-13 promote fibrocyte differentiation without inducing fibrocyte or fibrocyte precursor proliferation. We also find that the potent, antifibrotic cytokines IFN-␥ and IL-12 inhibit fibrocyte differentiation. In our culture system, IL-1␤, IL-3, IL-6, IL-7, IL-16, GM-CSF, M-CSF, fetal liver tyrosine kinase 3, insulin growth factor 1, vascular endothelial growth factor, and TNF-␣ had no significant effect on fibrocyte differentiation. 
INTRODUCTION
Fibrosis involves an aberrant and excessive production of extracellular matrix (ECM) proteins, especially collagen and fibronectin, by fibroblasts and fibroblast-like cells [1] . Unlike orderly wound healing, a persistence of neutrophils, eosinophils, lymphocytes, and monocyte-macrophages leads to the maintenance of cytokine levels and the inhibition of enzymes that degrade ECM proteins [2] . These events, which are thought to be a result of repeated episodes of injury, generate positive-feedback loops that lead to increased ECM protein deposition. Fibrosis leads to dysfunction as a result of the functional constraints placed by the fibrotic lesion on the given tissue or organ, as well as the alteration of the type and number of cells within tissues.
Much remains to be understood about the source of the fibroblast-like cells that are responsible for fibrosis as well as wound healing. The "classical" hypothesis is that local interstitial fibroblasts migrate into inflammatory areas and produce new ECM proteins, ultimately leading to fibrosis or wound healing [3] . One alternative hypothesis suggests that circulating bone marrow-derived precursors present within the blood are attracted to sites of injury, where they differentiate into spindle-shaped, fibroblast-like cells called fibrocytes and at least in part, mediate tissue repair and fibrosis [4 -9] . Fibrocytes express markers of hematopoietic cells (CD45, MHC class II, CD34) and stromal cells (collagens I and III and fibronectin) [4, 5, 10 -12] . Fibrocyte precursors appear to differentiate from a subpopulation of CD14ϩ peripheral blood monocytes [5, 10 -12] . We have shown that fibrocyte differentiation can be inhibited in vitro and in vivo by the plasma protein serum amyloid P (SAP) and aggregated IgG [11] [12] [13] [14] [15] .
One of the key features of fibrosis is a distinctive cytokine profile with elevated levels of profibrotic Th-2 cytokines such as IL-4 and IL-13 [16 -18] . These profibrotic Th-2 cytokines stimulate collagen production and deposition by fibroblasts and promote the activation and differentiation of these fibroblasts to a more active cell type, the myofibroblast [19] . Many fibrotic lesions are associated with this Th-2 inflammatory environment including asthma, scleroderma (systemic sclerosis), cardiac fibrosis, hepatic fibrosis, early rheumatoid arthritis, thermal injury, hypertrophic scars, and various lung-fibrosing pathologies [16, 20 -24] . In all of these cases, elevated levels of one or more profibrotic cytokines (IL-4, IL-10, IL-13, or TGF-␤) appear to correlate with disease progression.
The effects of cytokines on cells can be observed by their effects on signal transduction pathways. For example, IL-4 binds to IL-4R␣, whereas IL-13 binds to IL-13R␣1. After binding IL-4, IL-4R␣ then associates with the common ␥-chain of the IL-2R family or with the IL-13R␣1 chain for signaling [25, 26] . For IL-13 signaling, IL-13R␣1 associates with IL-4R␣ to generate a signaling complex. IL-4 or IL-13 signaling induces the phosphorylation and dimerization of the cytoplasmic transcription factor STAT-6 [27, 28] .
The profibrotic Th-2 cytokines are regulated in part by the presence of Th-1 cytokines, such as IL-12 and IFN-␥. The  Th-1 and Th-2 cytokine groups exert reciprocal, inhibitory  effects on each other, and the presence of IL-12 or IFN-␥  inhibits IL-4 or IL-13 responses and vice versa [16, 29, 30] . In hematopoietic cells, IL-12 signaling leads to the specific activation of STAT-4, whereas IFN-␥ activates primarily STAT-1 [27, 28, 31] .
As cytokines such as IL-4 and IL-13 are associated with wound healing and fibrosis, and fibrocytes are also associated with wound healing and fibrosis, we examined the effect of cytokines on fibrocyte differentiation [16, 17, 21] . We find that IL-4 and IL-13 promote fibrocyte differentiation without inducing proliferation, whereas IL-12 and IFN-␥ inhibit fibrocyte differentiation. We also show that IL-4, IL-13, and IFN-␥ act directly on monocytes to regulate fibrocyte differentiation. In competition studies, we find that IL-4 and IL-13 counteract IL-12 and IFN-␥, and vice versa but that the fibrocyte-inhibitory activity of SAP is dominant over IL-4 and IL-13. These data suggest that the cytokine milieu present at sites of wound healing, inflammation, and fibrosis have a profound effect on the ability of monocytes to differentiate into fibrocytes.
MATERIALS AND METHODS

Cell culture and fibrocyte differentiation assay
Blood was collected from healthy adult volunteers in accordance with Rice University's Institutional Review Board (Houston, TX, USA). PBMCs were isolated from heparinized blood by Ficoll-Paque Plus (GE Healthcare Biosciences, Piscataway, NJ, USA) as described previously [11, 12] . PBMCs were incubated in serum-free medium (SFM), which consists of RPMI 1640 (SigmaAldrich, St. Louis, MO, USA), supplemented with 10 mM HEPES (SigmaAldrich), nonessential amino acids (Sigma-Aldrich), 1 mM sodium pyruvate (Sigma-Aldrich), 2 mM glutamine (Invitrogen, Carlsbad, CA, USA), 100 U/ml penicillin, 100 g/ml streptomycin (Sigma-Aldrich), and ITSϩ3 (Sigma-Aldrich). PBMCs were cultured in flat-bottomed, 96-well, tissue-culture plates in 200 l vol at 2.5 ϫ 10 5 cells per ml in a humidified incubator containing 5% CO 2 at 37°C for the indicated times. Cytokines (all from Peprotech, Rocky Hill, NJ, USA) and SAP (EMD Biosciences, San Diego, CA, USA) were added at the indicated concentrations. Commercial SAP preparations contain 140 mM NaCl, 10 mM Tris, 0.1% azide, and 10 mM EDTA, which may influence many cellular processes. Therefore, we routinely buffer-exchange SAP into 20 mM sodium phosphate, pH 7.4. Briefly, SAP preparations are diluted 1:1 vol:vol with 20 mM sodium phosphate, pH 7.4, and added to 10 kDa cutoff centrifugal filters (Microcon YM-10, Millipore, Billerica, MA, USA) and centrifuged at 10,000 g for 10 min. The upper reservoir is then resuspended with ϳ400 l 20 mM phosphate buffer and centrifuged again. This process is repeated four times to exchange the buffer to 20 mM sodium phosphate. Buffer-exchanged preparations were then checked by protein assay, chromatography on a Superose 12 size-exclusion column (GE Healthcare Biosciences), and Coomassie-stained polyacrylamide gels to assess their concentration and purity. We routinely found that the buffer-exchanged SAP was Ͼ98% pure and is a 135-kDa complex of 27 kDa monomers. Fibrocytes were counted after culturing cells for 5 days. Cells were air-dried, fixed in methanol, and stained with eosin and methylene blue (Hema 3 Stain, Fisher Scientific, Hampton, NH, USA) [11, 12] . Fibrocytes from duplicate wells were counted in five different 900 m diameter fields per well, using the criteria of adherent cells with an elongated spindle shape and the presence of an oval nucleus. All cultures were counted by at least two independent observers. THP-1 cells (American Type Culture Collection, Manassas, VA, USA) were cultured in RPMI 1640 containing 10% FCS, 100 U/ml penicillin, 100 g/ml streptomycin (Sigma-Aldrich), and 2 mM glutamine (Invitrogen) at 2 ϫ 10 4 cells per ml and subcultured when cell concentrations reached 5 ϫ 10 5 cells/ml.
Preparation of monocytes
To determine if cytokines have a direct effect on monocytes, we depleted lymphocytes and dendritic cells using negative selection with magnetic Dynabeads (Dynal-Biotech, Invitrogen), as described previously [11, [32] [33] [34] [35] 
Immunohistochemistry
PBMCs were cultured on eight-well glass microscope slides (Lab-Tek, Nalge Nunc International, Naperville, IL, USA) for 5 days as described previously [11, 12] . Slides were air-dried for at least 60 min before fixation in acetone for 15 min. Nonspecific binding was blocked by incubation in 4% BSA (Fraction V, Sigma-Aldrich) in PBS for 60 min. Slides were incubated with 5 g/ml primary antibodies in PBS containing 4% BSA for 60 min. Slides were stained with CD14 (clone MEM-18), CD34 (clone QBend10, mouse IgG1, Beckman Coulter, Fullerton, CA, USA), CD43 (clone 1G10, mouse IgG1, BD Biosciences), pan-CD45, or proliferating cell nuclear antigen (PCNA; clone PC10, mouse IgG2a, EMD Biosciences, San Diego, CA, USA). Collagen I was stained with rabbit polyclonal antibody (600-401-103, Rockland Inc., Gilbertsville, PA, USA), and collagen III was stained with rabbit polyclonal 600-401-105 (Rockland Inc.). Isotype-matched, irrelevant mouse mAb (BD Biosciences) or irrelevant rabbit polyclonal antibodies (Jackson ImmunoResearch, West Grove, PA, USA) were used as controls. Slides were then washed in six changes of PBS over 30 min and incubated for 30 min with 2.5 g/ml biotinylated goat F(abЈ) 2 anti-mouse IgG or biotinylated goat F(abЈ) 2 antirabbit IgG (both cross-adsorbed against human Ig, Southern Biotechnology). After washing, the biotinylated antibodies were detected by ExtrAvidin alkaline phosphatase (Sigma-Aldrich) in PBS containing 4% BSA. Staining was developed with the Vector Red alkaline phosphatase kit (Vector Laboratories, Burlingame, CA, USA) for 5 min. Sections were then counterstained for 10 s with Gill's hematoxylin #3, diluted 1:5 with water (Sigma-Aldrich), rinsed in water, and then treated with Scott's tap water substitute for 2 min. Slides were then dehydrated through 70%, 95%, and 100% ethanol, cleared with xylene, and mounted with Permount (VWR, West Chester, PA, USA). All procedures were performed at room temperature.
Phosphoprotein analysis by flow cytometry
Detection of phosphorylated STAT proteins was performed as described previously [37] [38] [39] . Briefly, PBMCs were stimulated for 15 min at 37°C in SFM containing cytokines as indicated and were then washed twice in ice-cold PBS. PBMCs were then incubated with 5 g/ml CD14-biotin (Serotec) for 30 min on ice. PBMCs were then fixed in 1.6% paraformaldehyde in PBS for 10 min at room temperature and then washed twice in ice-cold PBS. The cell pellet was then resuspended in ice-cold methanol and incubated overnight at -20°C. Cells were then washed three times in ice-cold PBS before staining on ice for 60 min with a 1/50 dilution of Alexa 488-conjugated, antiphosphorylated STAT antibodies or Alexa 488-conjugated, irrelevant antibodies (all from BD Biosciences) in PBS containing 4% BSA. PBMCs were then washed twice in PBS and then incubated with a 1/100 dilution of streptavidin-PerCP (BD Biosciences) in PBS containing 4% BSA for 30 min. PBMCs were washed twice in PBS and then resuspended in PBS containing 2% BSA and analyzed by flow cytometry using a FACScan (BD Biosciences), analyzing ϳ20,000 events [40] . Data were analyzed using WinMDI software (WinMDI Version 2.8, 2000, written by Joe Trotter, Flow Cytometry Core Facility, The Scripps Institute, La Jolla, CA, USA).
Videomicroscopy
PBMCs were cultured in SFM in the presence or absence of cytokines in eight-well slides (#1 coverglass, Nalge Nunc International) in 400 l vol at 5 ϫ 10 5 cells per ml in a humidified incubator containing 5% CO 2 at 37°C. For videomicroscopy, an Imagepoint charged-coupled device (CCD) camera (Photometrics, Tucson, AZ, USA), mounted on a Nikon TMS inverted microscope with a 10ϫ objective and a blue filter on the illuminator, was placed in the incubator. The CCD used an exposure integration of 4 and a 21-dB gain, and to prevent condensation, the Peltier cooler was disconnected. An external power supply was used to operate the TMS 6V illuminator lamp at 2.3 V/1.8 A. Output from the CCD camera was recorded on S-VHS tape on an AG-6740 time-lapse video recorder (Panasonic, Secaucus, NJ, USA) set at 960 H.
Statistics
Statistical analysis was performed using GraphPad Prism software (GraphPad Software, San Diego, CA, USA). Differences between two groups were assessed by Student's t-test. Differences between multiple groups were assessed by ANOVA using Tukey's post-test. Significance was defined as P Ͻ 0.05. In the figures, * indicates P Ͻ 0.05; ** indicates P Ͻ 0.01.
RESULTS
IL-4 and IL-13 promote, whereas IL-12 and IFN-␥ inhibit, fibrocyte differentiation
As SAP and aggregated IgG inhibit fibrocyte differentiation, it is possible that other molecules that bind to and activate monocytes could also regulate fibrocyte differentiation [11, 12] . Therefore, we tested if potent monocyte activators, such as the inflammatory cytokines IL-1␤, IL-6, IL-12, IL-18, IFN-␥, and TNF-␣; differentiation-inducing cytokines, such as IL-3, GM-CSF, and M-CSF; or cytokines associated with fibrosis, such as IL-4 and IL-13, could influence fibrocyte differentiation. The levels of cytokines found in wound fluid, inflammatory lesions, and fibrosis are generally within the 100-to 10,000-pg/ml range [21, [41] [42] [43] . PBMCs were cultured for 5 days in SFM with cytokines in a dose range from 0.001 to 100 ng/ml. Of the profibrotic cytokines tested, only in cultures containing IL-4 and IL-13 was there an increase in the number of fibrocytes (Fig. 1 , A and C; see below for evidence that these are fibrocytes). The effects of IL-4 and IL-13 were statistically significant at 1 and 10 ng/ml, respectively, whereas a range of other cytokines had no statistically significant effect (Figs. 1C  and 2 ). In contrast, the presence of IFN-␥ or IL-12 led to a statistically significant inhibition of fibrocyte differentiation at 1 ng/ml and above (Figs. 1, A-C, and 2). These data suggest that fibrocyte differentiation is enhanced by IL-4 or IL-13 and inhibited by IFN-␥ or IL-12 and that IL-1␤, IL-3, IL-6, IL-7, IL-16, GM-CSF, M-CSF, FLT-3, IGF-1, VEGF, and TNF-␣ do not appear to affect the number of fibrocytes after 5 days in our culture conditions ( Figs. 1 and 2) . 
IL-4 and IL-13 promote fibrocyte differentiation without altering morphology or phenotype
To determine if the presence of IL-4 or IL-13 alters the morphology of fibrocytes, PBMCs were cultured with cytokines for 5 days in SFM and then air-dried and stained with eosin and methylene blue. In cultures without the addition of exogenous cytokines, fibrocytes and monocyte/macrophages were readily detectable (Fig. 3A) . When cultured in the presence of IL-4 or IL-13, the elongated, spindle-shaped fibrocytes (Fig. 3 , solid arrows) were more numerous, compared with cells cultured without the addition of exogenous cytokines, but there were no discernable effects on the morphology of the fibrocytes (Fig. 3, B and C) . When cultured in the presence of IL-12 or IFN-␥, the numbers of fibrocytes were reduced, compared with cells cultured without the addition of exogenous cytokines (Fig.  3, D and E) . IL-12 and IFN-␥ are classical macrophageactivation agents [31, 44] , and as expected, the presence of IL-12 or IFN-␥ led to an increase in the number of macrophages (Fig. 3, D and E, open arrows) . IL-4 and IL-13 had no obvious effect on the number of macrophages. These data 5 cells per ml were cultured in eight-well glass slides in SFM for 5 days in the presence or absence of 3 ng/ml IL-4 or IL-13. Cells were then air-dried, fixed in acetone, and stained with antibodies. At least 100 elongated cells with oval nuclei were examined from at least 10 randomly selected fields, and the percentage of elongated cells that were positively stained by antibodies against the indicated markers is expressed as the mean Ϯ SEM (nϭ3 separate donors).
indicate that IL-4 and IL-13 increase the number of spindleshaped fibrocytes without altering the morphology of these cells.
To confirm that the elongated, spindle-shaped cells are fibrocytes and to test if the presence of IL-4 or IL-13 altered their expression of some of the known fibrocyte markers, we stained the cells for markers expressed by fibrocytes. In cultures without the addition of exogenous cytokines, more than 95% of the elongated, spindle-shaped cells expressed CD34, CD43, CD45, and collagen-I and -III (Figs. 3F and 4) . When cultured in the presence of IL-4 or IL-13, the elongated cells were likewise positive for CD34, CD43, CD45, and collagen-I (Figs. 3F and 4 and data not shown) . These data indicate that IL-4 and IL-13 increase the number of CD34-, CD43-, CD45-, and collagen-I-positive fibrocytes without altering their expression of these markers. As observed previously [45] [46] [47] , when cultured in the presence of IL-4 or IL-13, the macrophages were positive for CD206 and CD209, whereas in cultures containing IL-12 or IFN-␥, the macrophages were positive for CCR7 (data not shown).
Direct and indirect effect of cytokines on monocyte-to-fibrocyte differentiation
Fibrocyte precursors appear to differentiate from a subpopulation of CD14ϩ peripheral blood monocytes [5, 10 -12] . To determine whether cytokines regulate fibrocyte differentiation by directly affecting monocytes or affect other cells present in the PBMC population, which then affect monocytes, we incubated purified monocytes with cytokines. To obtain monocytes, PBMCs were depleted of B cells, NK cells, T cells, and dendritic cells by negative selection. This generally produced a population of monocytes that were more than 98% monocytes (data not shown) [11, 12, [32] [33] [34] [35] , which were then cultured for 5 days in SFM containing IL-4, IL-12, IL-13, or IFN-␥. When cultured in SFM, ϳ4% of the purified monocytes differentiated into fibrocytes at 5 days. As observed with PBMCs ( Figs. 1 and  5A) , the addition of IL-4 or IL-13 to purified monocytes increased the numbers of fibrocytes seen at 5 days (Fig. 5B) . The addition of IFN-␥ to purified monocytes decreased the number of fibrocytes at 5 days (Fig. 5B) . Compared with PBMCs, IL-12 did not affect the ability of purified monocytes to differentiate into fibrocytes (Fig. 5B) . To more easily compare the response of PBMCs and monocytes to cytokines, we re-analyzed the data from Figure 5 , A and B, as the mean Ϯ SEM of the percent of SFM control. This shows that IL-12 only had a significant inhibitory effect on fibrocyte differentiation in whole PBMCs. These data suggest that IL-4, IL-13, and IFN-␥ may have a direct action on monocytes, whereas IL-12 does not act directly on monocytes to regulate fibrocyte differentiation.
To confirm that IL-4, IL-13, and IFN-␥ were having a direct effect on monocytes, we analyzed STAT protein phosphorylation, which is a characteristic for these cytokines [27, 28] . PBMCs were incubated for 15 min, which is the optimal time for STAT activation [37] [38] [39] 41] , in SFM or SFM containing IL-4, IL-13, or IFN-␥. PBMCs were then fixed and stained for phosphorylated STAT proteins. As expected, PBMCs incubated for 15 min in SFM without exogenous cytokines did not lead to any discernable STAT activation (Fig. 6A, histograms  c and d ). PBMCs incubated with IL-4 generated a phosphorylated STAT-6 response in lymphocytes and monocytes (Fig. 6 , A, histograms e and f, and B, histograms a and b), whereas IL-13 generated a phosphorylated STAT-6 response that was restricted to monocytes (Fig. 6 , A, histograms g and h, and B, histograms c and d). PBMCs cultured in the presence of IFN-␥ generated a phosphorylated STAT-1 response, which was also restricted to monocytes (Fig. 6 , A, histograms i and j, and B, histograms e and f). As a control, we analyzed STAT-3 and STAT-5 activation, which was not significantly phosphorylated by any of the cytokines used (data not shown). We were unfortunately unable to acquire reliable phosphorylated STAT-4 data, so we were unable to analyze IL-12-generated STAT signaling data (data not shown). However, these data do indicate that IL-4, IL-13, and IFN-␥ directly act on the monocyte population to generate a signaling cascade, which may influence the differentiation of monocytes into fibrocytes.
We also analyzed a series of depletion experiments, where we were unable to purify monocytes to greater than 98% purity. In these experiments, we depleted the B cells, T cells, and dendritic cells but were left with a population of contaminating, CD16-positive NK cells, as determined by flow cytometry. To determine whether the number of residual, CD16-positive NK cells in the monocyte preparations influenced the effect of IL-12, the percent of CD16-positive NK cells in the monocyte preparation was correlated with the effect of IL-12 (ratio of fibrocytes that differentiate in SFM with IL-12 vs. SFM alone). We found an inverse correlation (r 2 ϭ0.7096; nϭ6) between the number of fibrocytes and the number of contaminating NK cells (Fig. 7A) . In comparison, we analyzed the effect of residual, CD16-positive NK cells in the monocyte preparation on the effect of IFN-␥ (ratio of fibrocytes that differentiate in SFM with IFN-␥ vs. SFM alone). We found no significant correlation (r 2 ϭ0.0119; nϭ6) between the number of fibrocytes and the number of contaminating NK cells (Fig. 7B) . Together, these data suggest that the inhibitory effect of IL-12 on fibrocyte differentiation in the PBMC population was probably a result of an indirect effect, where IL-12 stimulated NK cells to secrete other factor(s) such as IFN-␥ [48 -50] , which then directly acted on monocytes to inhibit fibrocyte differentiation.
IL-4 and IL-13 promote fibrocyte differentiation without inducing proliferation
There are two possible mechanisms by which IL-4 and IL-13 could increase the number of fibrocytes observed at 5 days. First, IL-4 or IL-13 could induce the proliferation of fibrocyte precursors or fibrocytes. Second, IL-4 or IL-13 could increase the number of fibrocytes that differentiate from a precursor population. To distinguish between these possibilities, we videotaped PBMCs in culture continuously for 8 days, starting when cells were first plated into the culture well. We were unable to detect any PBMCs that divided over this time-frame when cultured in the presence or absence of IL-4 or IL-13, although we could readily observe enhanced fibrocyte differentiation when IL-4 or IL-13 was present compared with no added cytokine (data not shown). Specifically, when we observed fibrocytes backward in time on the videotapes to when they were initially added to the chamber slides, we never saw fibrocytes or their precursors divide, even in the presence of IL-4 or IL-13. To further assess proliferation, PBMCs that were cultured in the presence or absence of IL-4 or IL-13 were stained with PCNA, a marker of proliferating cells [51] [52] [53] . We were unable to detect fibrocytes expressing PCNA, although control cultures of THP-1 cells had readily detectable PCNA in the nucleus of dividing cells (data not shown). These data suggest that IL-4 and IL-13 promote an increased number of precursor cells to differentiate into fibrocytes rather than inducing fibrocyte proliferation.
SAP, but not IL-12 or IFN-␥, can inhibit IL-4-or IL-13-induced fibrocyte differentiation
As inflammatory and fibrotic environments rarely, if ever, contain single cytokines and to further understand the effects of cytokines on fibrocyte differentiation, we examined the effects of stimulating PBMCs with combinations of cytokines. PBMCs were cultured in SFM with increasing concentrations of the fibrocyte-inhibiting cytokines IL-12 or IFN-␥ in the absence or presence of the fibrocyte-promoting cytokines IL-4 or IL-13 (Fig. 8) . As expected, compared with PBMCs cultured without exogenous cytokines, PBMCs cultured in SFM containing increasing concentrations of IL-12 or IFN-␥ had significantly lower numbers of fibrocytes, as determined by Student's t-test (SFM vs. 100 ng/ml IL-12, Pϭ0.0008: SFM vs. 100 ng/ml IFN-␥, Pϭ0.0034; Fig. 8, A and B) . However, the presence of an intermediate dose of 3 ng/ml IL-4 or IL-13 could significantly counteract the ability of IL-12 or IFN-␥ to decrease the number of fibrocytes (Fig. 8, A and B) . These data indicate that IL-4 or IL-13 can counteract IL-12 or IFN-␥ and vice versa.
We previously found that SAP is a potent inhibitor of fibrocyte differentiation [11] [12] [13] 15] . To determine if SAP could counteract the profibrotic cytokines IL-4 or IL-13, we cultured PBMCs in SFM with increasing concentrations of SAP in the absence or presence of IL-4 or IL-13 (Fig. 8C) . As expected, PBMCs cultured in SFM containing increasing concentrations of SAP had significantly lower numbers of fibrocytes, as determined by Student's t-test (SFM vs. 4 g/ml SAP, Pϭ0.0031; Fig. 8C ). In the presence of 3 ng/ml IL-4 or IL-13, this inhibitory activity was maintained (Fig. 8C) . These data indicate that the fibrocyte-inhibitory activity of SAP has a dominant effect over the fibrocyte-promoting activities of IL-4 and IL-13.
DISCUSSION
In humans, fibrocytes have been detected in tumors, skin wounds, hypertrophic scars, bronchial asthma, pulmonary fibrosis, and nephrogenic fibrosing dermopathy [6, 54 -57] . In animal models, fibrocytes are associated with experimental lung, kidney, and liver fibrosis, intimal hyperplasia of the carotid artery, chronic granuloma formation, and skin wounding [6, 58 -65] . We have also recently shown that fibrocytes are involved in cardiac fibrosis following ischemia-reperfusion injury in mice and bleomycin-induced lung fibrosis in rats and mice and that the fibrocytes and the fibrosis associated with these processes are inhibited by SAP [13, 15] . These studies clearly indicate that bone marrow-derived fibrocytes are actively involved in many forms of fibrosis.
We found that IL-4 and IL-13 promote fibrocyte differentiation, whereas IL-12 and IFN-␥ inhibit fibrocyte differentiation. IL-4, IL-13, and IFN-␥ appear to act directly on monocytes, whereas IL-12 acts indirectly, possibly through NK cells. In proinflammatory "Th-1-like" diseases such as uveitis, there are elevated levels of IL-6, IFN-␥, and IL-12 [66 -68] . In pulmonary sacroidosis bronchoalveolar lavage (BAL) fluid samples, there are elevated levels of IL-12 and IFN-␥ [69, 70] . Also in the BAL of patients with lung infections, the predominant cytokines include IFN-␥ and IL-12 [42] . In profibrotic diseases, such as systemic sclerosis, asthma, and idiopathic pulmonary fibrosis, there are elevated levels of IL-4 and IL-13 [43, 69, 71, 72] . Reports measuring multiple cytokines from the same sample support these findings and indicate that it is Fig. 7 . Fibrocyte differentiation in monocyte cultures containing increasing numbers of CD16-positive NK cells. Monocyte preparations containing variable numbers of CD16ϩ NK cells were cultured at 2.5 ϫ 10 5 cells per ml in SFM for 5 days in the presence or absence of (A) 3 ng/ml IL-12 or (B) 3 ng/ml IFN-␥. Cells were then airdried, fixed, and stained, and fibrocytes were enumerated by morphology. Results are expressed as a correlation of the ratio of the number of fibrocytes that differentiate in cytokines compared with SFM (y-axis) and the percentage of CD14-negative, CD16-positive NK cells (x-axis). The solid line represents the regression line, and the dotted line shows the 95% confidence limits. rare to detect IL-4 or IL-13 without the presence of IL-12 or IFN-␥ [21, 73, 74] . These reports and our data suggest that in many chronic inflammatory conditions, the presence of IL-4 or IL-13, even when IL-12 or IFN-␥ are present, may promote, or at least maintain, fibrocyte differentiation and fibrosis. We have shown that 3 ng/ml IL-4 or IL-13 can compete with 100 ng/ml IL-12 and IFN-␥ to regulate fibrocyte differentiation. However, the molecular weights of these cytokines are different. Three of the recombinant cytokines have similar molecular weights: IL-4 is 15 kDa; IL-13 is 13 kDa; and IFN-␥ is 17 kDa. Therefore, 3 ng/ml IL-4 and IL-13 is ϳ200 M, and 3 ng/ml IFN-␥ is 176 M, indicating these cytokines are approximately equimolar. However, IL-12 is a heterodimer of one p35 and one p40 chain and has a corresponding molecular weight of 75 kDa. Therefore, 3 ng/ml IL-12 is 40 M, approximately one-fifth the concentration of the other three cytokines used. This indicates that IL-12 is a more potent cytokine on a molar basis at inhibiting fibrocyte differentiation.
The fibrocyte-inhibitory activity of SAP was dominant over the fibrocyte-promoting activity of IL-4 and IL-13. This suggests that if SAP is present at an inflammatory site, SAP may well prevent fibrocyte differentiation. Although the levels of SAP have been measured by many groups in the serum, plasma, and urine of healthy individuals and patients with a wide variety of diseases, the concentration of SAP at inflammatory sites is unknown [75] [76] [77] [78] [79] [80] . Immunohistochemical staining of SAP has shown that SAP is associated with extracellular tissues, especially reticulin and elastic fibers, found in kidney, skin, and blood vessels, but whether SAP, once bound to ECM, is still biologically active is unclear, and the actual concentration of biologically active SAP present in these sites is unknown [81] [82] [83] [84] [85] [86] .
How SAP enters the extracellular spaces is unclear. SAP is produced in the liver and like many other large serum proteins, is unlikely to easily cross the endothelial barrier found in noninflamed tissues without specialized transport mechanisms [87, 88] . However, during inflammation when the endothelial layer allows leakage of plasma into the extracellular tissues, SAP may readily enter an inflammatory site. The appearance of fibrocytes within experimental inflammatory lesions within 3-7 days of initiation indicates that the levels of biologically active SAP, or any other molecules that inhibit fibrocyte differentiation, soon fall below a threshold necessary to inhibit fibrocyte differentiation [4, 5, 13, 15, 55, 56, 59] . This then suggests that increasing levels of fibrocyte-inhibitory molecules, such as SAP, might then inhibit fibrosis, and conversely, decreasing levels of fibrocyte-inhibitory molecules or increasing the levels of fibrocyte-promoting molecules may promote wound healing.
